D
BioVaxys Technology Corp.
BVAXF
$0.0389
$0.00010.26%
D
Sell
1/23/2024Upgraded
BioVaxys Technology Corp. (BVAXF) was upgraded to D- from E+ on 1/23/2024 due to an increase in the volatility index and total return index.
BioVaxys Technology Corp. (BVAXF) was upgraded to D- from E+ on 1/23/2024 due to an increase in the volatility index and total return index.
E
Sell
1/5/2024Downgrade
BioVaxys Technology Corp. (BVAXF) was downgraded to E+ from D- on 1/5/2024 due to a decline in the volatility index.
BioVaxys Technology Corp. (BVAXF) was downgraded to E+ from D- on 1/5/2024 due to a decline in the volatility index.
D
Sell
12/15/2023Upgraded
BioVaxys Technology Corp. (BVAXF) was upgraded to D- from E+ on 12/15/2023 due to an increase in the total return index, volatility index and growth index. Operating cash flow increased 96.61% from -$525.5 to -$17.8, EBIT increased 34.77% from -$392.3 to -$255.9, and earnings per share increased from -$0.0084 to -$0.008.
BioVaxys Technology Corp. (BVAXF) was upgraded to D- from E+ on 12/15/2023 due to an increase in the total return index, volatility index and growth index. Operating cash flow increased 96.61% from -$525.5 to -$17.8, EBIT increased 34.77% from -$392.3 to -$255.9, and earnings per share increased from -$0.0084 to -$0.008.
E
Sell
4/6/2023Downgrade
BioVaxys Technology Corp. (BVAXF) was downgraded to E+ from D- on 4/6/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.11 to 0.08.
BioVaxys Technology Corp. (BVAXF) was downgraded to E+ from D- on 4/6/2023 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 0.11 to 0.08.
D
Sell
3/31/2023Upgraded
BioVaxys Technology Corp. (BVAXF) was upgraded to D- from E+ on 3/31/2023 due to an increase in the volatility index, total return index and valuation index.
BioVaxys Technology Corp. (BVAXF) was upgraded to D- from E+ on 3/31/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
3/16/2023Downgrade
BioVaxys Technology Corp. (BVAXF) was downgraded to E+ from D- on 3/16/2023 due to a decline in the total return index and volatility index.
BioVaxys Technology Corp. (BVAXF) was downgraded to E+ from D- on 3/16/2023 due to a decline in the total return index and volatility index.
D
Sell
3/8/2023Downgrade
BioVaxys Technology Corp. (BVAXF) was downgraded to D- from D on 3/8/2023 due to a significant decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.0072 to -$0.0606, operating cash flow declined 166.72% from -$58.9 to -$157.1, and EBIT declined 1.44% from -$650.6 to -$660.
BioVaxys Technology Corp. (BVAXF) was downgraded to D- from D on 3/8/2023 due to a significant decline in the solvency index, growth index and total return index. Earnings per share declined from -$0.0072 to -$0.0606, operating cash flow declined 166.72% from -$58.9 to -$157.1, and EBIT declined 1.44% from -$650.6 to -$660.
D
Sell
2/23/2023Upgraded
BioVaxys Technology Corp. (BVAXF) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
BioVaxys Technology Corp. (BVAXF) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index.
D
Sell
2/8/2023Downgrade
BioVaxys Technology Corp. (BVAXF) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index and volatility index. The quick ratio declined from 0.16 to 0.05.
BioVaxys Technology Corp. (BVAXF) was downgraded to D- from D on 2/8/2023 due to a noticeable decline in the solvency index and volatility index. The quick ratio declined from 0.16 to 0.05.
D
Sell
9/8/2022Upgraded
BioVaxys Technology Corp. (BVAXF) was upgraded to D from D- on 9/8/2022 due to a major increase in the growth index. Earnings per share increased from -$0.0104 to -$0.0086, and EBIT increased 9.47% from -$865.2 to -$783.3.
BioVaxys Technology Corp. (BVAXF) was upgraded to D from D- on 9/8/2022 due to a major increase in the growth index. Earnings per share increased from -$0.0104 to -$0.0086, and EBIT increased 9.47% from -$865.2 to -$783.3.
D
Sell
3/4/2022Downgrade
BioVaxys Technology Corp. (BVAXF) was downgraded to D- from D on 3/4/2022 due to a major decline in the growth index, efficiency index and total return index. EBIT declined 194.26% from -$644.1 to -$1.9M, net income declined 172.25% from -$736.3 to -$2M, and earnings per share declined from -$0.0089 to -$0.0219.
BioVaxys Technology Corp. (BVAXF) was downgraded to D- from D on 3/4/2022 due to a major decline in the growth index, efficiency index and total return index. EBIT declined 194.26% from -$644.1 to -$1.9M, net income declined 172.25% from -$736.3 to -$2M, and earnings per share declined from -$0.0089 to -$0.0219.
D
Sell
11/3/2021Upgraded
BioVaxys Technology Corp. (BVAXF) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index, growth index and volatility index. EBIT increased 40.58% from -$1.08M to -$644.1, and earnings per share increased from -$0.0146 to -$0.0089.
BioVaxys Technology Corp. (BVAXF) was upgraded to D from D- on 11/3/2021 due to an increase in the total return index, growth index and volatility index. EBIT increased 40.58% from -$1.08M to -$644.1, and earnings per share increased from -$0.0146 to -$0.0089.
D
Sell
7/1/2021Upgraded
BioVaxys Technology Corp. (BVAXF) was upgraded to D- from E on 07/01/2021.
BioVaxys Technology Corp. (BVAXF) was upgraded to D- from E on 07/01/2021.
E
Sell
6/30/2021None
BioVaxys Technology Corp. (BVAXF) was downgraded to E from U on 06/30/2021.
BioVaxys Technology Corp. (BVAXF) was downgraded to E from U on 06/30/2021.
OTC PK
03/17/2025 2:52PM Eastern
Quotes delayed
